Cadexomer iodine
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
(what is this?) (verify) |
Cadexomer iodine is an
History
Cadexomer iodine was developed in the early 1980s in Sweden by
Properties
When formulated as a topical wound dressing, Iodosorb adsorbs exudate and particulate matter from the surface of granulating wounds and, as the dressing becomes moist, iodine is released. The product thus has the dual effect of cleansing the wound and exerting a bactericidal action. The bactericidal mechanism of cadexomer iodine is effective against methicillin-resistant Staphylococcus aureus (MRSA) and may prevent MRSA proliferation in the wound bed.[5] This is especially significant because bacteria populations have shown no sign of developing a resistance to iodine since it was first used for wound treatment in the middle of the 19th century.[6]
Uses
In addition to other manufacturers, Smith & Nephew distributes cadexomer iodine as Iodosorb and Iodoflex in many countries of the world for the treatment and healing of various types of wounds. The dosage forms are a paste dressing, an ointment and a gel, all of which contain 0.9% iodine. It is available in India under brand name Cadomer and is sold by JB Chemicals.[7]
See also
References
- ^ Merck Index, 14th Edition, p262 Merck & Co. Inc.
- S2CID 6759410.
- PMID 3926169.
- ^ Drosou A, Falabella A, Kirsner R (May 2003). "Antiseptics on wounds: an area of controversy. Wounds". 15 (5): 149–66. Retrieved 3 February 2009.
{{cite journal}}
: Cite journal requires|journal=
(help) - PMID 10037509.
- S2CID 1391248.
- ^ "Cadomer(Cadexomer Iodine)-Physician Information Page". Medical Dialogues. 21 August 2020. Retrieved 21 August 2020.